La eficacia de azitromicina en el tratamiento del asma bronquial refractario a la terapia convencional
DOI:
https://doi.org/10.31053/1853.0605.v75.n3.17736Palavras-chave:
asma severo, bronquiectasias, azitromicinaResumo
Nosotros sugerimos que la TACAR del tórax debió formar parte de la metodología en esta publicación y que constituye una recomendación para la evaluación del Asma refractario al tratamiento en la práctica clínica.
Downloads
Referências
1. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Marks GB, Baraket M, Powell H, Taylor SL, Leong LEX, Rogers GB, Simpson JL. Lancet 2017; 390: 659–68.
2. Comorbidities in adults with asthma: Population-based cross-sectional analysis of 1.4 million adults in Scotland. Weatherburn CJ, Guthrie B, Mercer SW, Morales DR. Clin Exp Allergy, 2017;1–7.
3. Co-morbidities in severe asthma: Clinical impact and management. Porsbjerg C, Menzies A. Respirology, 2017; 22: 651–661.
4. Investigation of bronchiectasis in severe uncontrolled asthma. Dimakou K, Gousiou A, Toumbis M, Kaponi M, Chrysikos S, Thanos L, Triantafillidou. Clin Respir J. 2017;1–7.
5. Qualitative Analysis of High-Resolution CT Scans in Severe Asthma. Gupta S, Siddiqui S, Haldar P, Raj V, Entwisle JJ, Wardlaw AJ, Bradding P, Pavord ID, Green RH, Brightling CE. CHEST 2009; 136:1521–1528.
6. Bronchiectasthma and asthmectasis. Soriano JB, Serrano J. Eur Respir J 2016; 47: 1597–1600.
7. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. Lancet 2012; 380: 660–67.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2018 Universidad Nacional de Córdoba
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
A geração de trabalhos derivados é permitida, desde que não seja feita para fins comerciais. O trabalho original não pode ser usado para fins comerciais.